Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Setmelanotide.

Research draft

Setmelanotide is a melanocortin-4 receptor agonist used for defined rare obesity conditions.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Setmelanotide is a melanocortin-4 receptor agonist used for defined rare obesity conditions.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It targets appetite-regulation signalling in the melanocortin pathway.

Human research

Randomised and disease-specific trials support selected indications; these do not establish treatment for all obesity.

Preclinical & other research

Genetic and receptor research provides the disease rationale.

Safety & unknowns

Pigmentation, mood-related and sexual-function adverse effects require the current label.

Regulatory status

Imcivree has indication-specific approvals; eligibility and newer indications must match the local label.

Reported use & evidence

Research profile draft

The supplied Setmelanotide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds